Navigation Links
Opsona Therapeutics Closes EUR18M Funding
Date:2/18/2009

anised monoclonal antibody (OPN-305) to a key toll-like receptor (TLR) target, has demonstrated efficacy in a number of animal models and will start pivotal clinical trials in 2010.

Florent Gros, managing director, Novartis Venture Fund added, "We are delighted to be working with Opsona Therapeutics and the other investors to assist Opsona in progressing the company's highly innovative technology and approaches towards the clinic. The innate immune system represents a new frontier in targeting inflammatory diseases, and the caliber of the investors in this funding round is a demonstration of Opsona's expertise and capabilities in this highly promising field.'

Opsona has also announced the opening of a new facility in Switzerland. The Swiss laboratory will carry out pivotal assay development and biochemical work for new projects and therapeutics recently acquired by Opsona to expand its pipeline of immunomodulators. The expertise that it intends to grow in Switzerland will complement the existing team and activity in Dublin.

Dr Cormac Kilty, Chairman of Opsona and past Chairman of the Irish Bioindustry Association explains "This is major achievement for any biotechnology company in the current economic climate. Opsona's R&D shows that emerging Irish companies can reach international recognition in biotechnology."

Notes to Editors:

About Opsona Therapeutics

Opsona is a drug development company, focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. The company was founded in 2004 with three of Trinity College Dublin's respected Immunologists (Professors Luke O'Neill, Kingston Mills and Dermot Kelleher). The company is specifically interested in drugs which modulate the innate immune system and its signalling, specifically Toll-Like Receptors (TLR). Opsona has a pipeline of therapeutics in advanced pre-clini
'/>"/>

SOURCE Opsona Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... live in each person,s digestive tract. Scientists believe that ... off harmful infections, but their role in human health ... on the role of these bacteria, a team of ... tracked fluctuations in the bacterial populations of two research ... the July 25 issue of the journal Genome ...
(Date:7/25/2014)... , July 25, 2014 ... the "Global Metabolomics Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics is ... Metabolomics has become a new experimental technique that ... the environmental sciences. Metabolites are small molecules that ...
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... Livermore, California (PRWEB) July 25, 2014 ... been named to Thomson Reuters list of " The ... Pitz are part of the 3,000 researchers who were ... years to recognize those who published the highest-impact work ... numerous research papers on combustion modeling . , ...
Breaking Biology Technology:Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4
... tumor,s vulnerability yields durable responses in Phase I/II ... ... 21 Systems Medicine, LLC (SM),a wholly-owned subsidiary of Cell Therapeutics, ... phase I trial,combining cisplatin with brostallicin in patients with solid tumors ...
... Nov. 21 Syngenta and the Royal,Society of Chemistry ... to help promote the economic and social development of,the ... continent,is being established initially in Kenya. Its purpose is ... to achieve greater levels of,innovation and scientific development., ...
... paper to be published Nov. 22 in the online ... of Wisconsin-Madison researchers reports the genetic reprogramming of human ... cells., The finding is not only a critical scientific ... landscape of stem cell biology as human embryos may ...
Cached Biology Technology:Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers 2Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers 3Syngenta and The Royal Society of Chemistry Launch African Science Initiative 2Syngenta and The Royal Society of Chemistry Launch African Science Initiative 3UW-Madison scientists guide human skin cells to embryonic state 2UW-Madison scientists guide human skin cells to embryonic state 3
(Date:7/28/2014)... became the first man to reach the South Pole ... an international team of scientists led by Joe McConnell ... air pollution from industrial activities arrived long before. , ... spaced locations around the Antarctic continent, including the South ... reconstruction to date of lead pollution over the Earth,s ...
(Date:7/27/2014)... largest prevalence studies to date, researchers from the U.K. ... the hepatitis C virus (HCV). Findings published in Hepatology, ... of Liver Diseases, indicate that genotype 1 is the ... of which one-third reside in East Asia. Genotype 3, ... most prevalent, followed by genotypes 2, 4, 6, and ...
(Date:7/27/2014)... shown the potential for global climate change to cut ... part, ignored the interactions between increasing temperature and air ... damage crops. , A new study involving researchers at ... suggesting that policymakers need to take both warming and ... The study looked in detail at global production of ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Hepatitis C virus genotype 1 is most prevalent worldwide 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
... among the authors of a new paper that describes ... when and how to use an environmental strategy known ... assistant professors of biology, and Alejandro Camacho, associate professor ... that produced the paper, which appears in this week,s ...
... are several risk factors for the development of Alzheimer,s ... of studies linking these risk factors with Vitamin D ... Journal of Alzheimer,s Disease (May 2009) by ... Health Research Center (SUNARC) suggests that further investigation of ...
... wounded during combat, surgeons must focus on reducing infection ... improve the repair and regeneration processes are being developed ... not being moved quickly enough into military trauma centers. ... for Advanced Bioengineering for Soldier Survivability want to change ...
Cached Biology News:Notre Dame researchers describe new tool for evaluating 'managed relocations' 2Notre Dame researchers describe new tool for evaluating 'managed relocations' 3Is vitamin D deficiency linked to Alzheimer's disease and vascular dementia? 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 3
... H3 (Lys 4) Immunogen: ... ...RT[ Ac K]Q... in which [ Ac ... human histone H3 Accession ... Weight: Mr ~17kDa ...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
b-Catenin (pSer675), phospho-specific...
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: